24 results
Recurrent / Breakthrough DVT During Anticoagulation

Subtherapeutic Anticoagulation
Hypercoagulable State 
 - Antithrombin deficiency 
 - Hypercoagulability ot
Breakthrough DVT During Anticoagulation ... Subtherapeutic Anticoagulation ... APLS - MPN/PNH ... Structural - Pelvic masses ... #hematology #differential
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
Over-anticoagulation ... management #algorithm #pharmacology ... #treatment #medications ... decisionaid #cardiology #hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
old, ~10,000 new cases ... only curative treatment ... Diagnosis #Management #treatment ... #hematology #oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... (A) Suggested treatment ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Ulcers: • Treatment ... immunosuppressive meds • +/- Anticoagulation ... (case by case) ... #management #pharmacology ... #rheumatology
Systemic Therapy for Hepatocellular Carcinoma - AGA Clinical Practice Guideline

First Line Treatment for HCC with Preserved
First Line Treatment ... Function Second Line Treatment ... #Management #Hepatology ... Gastroenterology #oncology ... #Pharmacology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Triggers: ATRA treatment ... myalgias, HoTN, edema ... Renal Failure Treatment ... diagnosis #management #hematology ... #oncology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
without other cause ... : 33% • Treatment ... with pulmonary edema ... : No • Treatment ... Transfusion #Reactions #hematology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology